{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:11:34Z","timestamp":1771881094727,"version":"3.50.1"},"reference-count":90,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1185\/030079902125000516","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T18:06:28Z","timestamp":1033495588000},"page":"269-276","source":"Crossref","is-referenced-by-count":136,"title":["Effects of Fibrates on Serum Metabolic Parameters"],"prefix":"10.1185","volume":"18","author":[{"given":"M.","family":"Elisaf","sequence":"first","affiliation":[{"name":"Professor of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199912000-00011"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00010-1"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1185\/0300799009117004"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.6.6.670"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420040119015"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/0021-9150(94)05375-S","article-title":"Micronized fenofibrate","volume":"110","author":"Munoz A","year":"1999","unstructured":"Munoz A, Guichard JP, Reginault PH. Micronized fenofibrate. Atherosclerosis 1999;110:S45\u2013S48","journal-title":"Atherosclerosis"},{"key":"e_1_2_1_8_1","first-page":"682","article-title":"The impact of micronized fenofibrate on lipid sub-fractions and on reaching HDL-targets in 7,098 patients with dyslipidaemia","volume":"6","author":"Poulter N","year":"1999","unstructured":"Poulter N. The impact of micronized fenofibrate on lipid sub-fractions and on reaching HDL-targets in 7,098 patients with dyslipidaemia. Br J Cardiol 1999;6:682\u20135","journal-title":"Br J Cardiol"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000213"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(93)90071-2"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.13.5.702"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)05465-U"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.2.282"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(85)90095-4"},{"key":"e_1_2_1_15_1","first-page":"231","article-title":"Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors","volume":"13","author":"Ganotakis ES","year":"1996","unstructured":"Ganotakis ES, Mikhailidis DP. Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. Today Therap Trends 1996;13:231\u201349","journal-title":"Today Therap Trends"},{"key":"e_1_2_1_16_1","first-page":"225","article-title":"Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate of lifestyle advance","volume":"17","author":"Mikhailidis DP","year":"1998","unstructured":"Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate of lifestyle advance. Int Angiol 1998;17:225\u201333","journal-title":"Int Angiol"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/204748739900600208"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(92)90007-4"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(92)90009-6"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(93)90067-5"},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/030006059202000301","article-title":"Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridemia: effect of gemfibrozil","volume":"20","author":"Ditschuneit HH","year":"1992","unstructured":"Ditschuneit HH, Fletchner-Mors M, et al. Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridemia: effect of gemfibrozil. J Intern Med Res 1992;20:197\u2013210","journal-title":"J Intern Med Res"},{"key":"e_1_2_1_22_1","first-page":"S42\u2013S47","article-title":"Ciprofibrate \u2013 a profile","volume":"69","author":"Betteridge DJ","year":"1993","unstructured":"Betteridge DJ. Ciprofibrate \u2013 a profile. Postgrad Med J 1993;69:S42\u2013S47","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_23_1","first-page":"109","article-title":"Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia","volume":"20","author":"Wolf HR","year":"1994","unstructured":"Wolf HR. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Drug Exp Clin Res 1994;20:109\u201313","journal-title":"Drug Exp Clin Res"},{"key":"e_1_2_1_24_1","first-page":"482","article-title":"Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study","volume":"12","author":"Cattin L","year":"1990","unstructured":"Cattin L, Da-Col PG, Feruglio FS, et al. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study. Clin Ther 1990;12:482\u20138","journal-title":"Clin Ther"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.13.2.286"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04209-4"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200112000-00003"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200112000-00004"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-001-0006-y"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-001-0015-x"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm990554g"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90586-8"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00918.x"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/31701"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)41090-9"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118118"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91343-4"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.7.2137"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.1.37"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.12.1585"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.23.2828"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.15.1773"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.85.5.394"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.45.32048"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.24.3125"},{"key":"e_1_2_1_49_1","unstructured":"Rizos E Kostoula A Elisaf M et al. Effect of ciprofibrate on CRP and fibrinogen levels. Angiology (in press)"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(96)05872-8"},{"key":"e_1_2_1_51_1","first-page":"1","volume-title":"XXII Congress of the European Society of Cardiology","author":"Elisaf M","year":"2001","unstructured":"Elisaf M, Tsimihodimos V, Bairaktari E, et al. Does micronized fenofibrate affect PAF-acetylhydrolase activity? XXII Congress of the European Society of Cardiology (Stockholm, Sweden, 1\u20135 September 2001)"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00734.x"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00283-X"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.22.16638"},{"key":"e_1_2_1_55_1","first-page":"2550","article-title":"Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations","volume":"81","author":"Jeng CY","year":"1996","unstructured":"Jeng CY, Sheu WH, Fuch MM, et al. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrin Metab 1996;81:2550\u20133","journal-title":"J Clin Endocrin Metab"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199608000-00009"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)05437-N"},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.11.1077"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-200109000-00005"},{"key":"e_1_2_1_60_1","first-page":"61","article-title":"A place for fibrinogen-lowering drugs in cardiovascular disease?","volume":"7","author":"Mikhailidis DP","year":"1995","unstructured":"Mikhailidis DP, Winder AF. A place for fibrinogen-lowering drugs in cardiovascular disease? J Drug Develop Clin Pract 1995;7:61\u201370","journal-title":"J Drug Develop Clin Pract"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.2991.409k03_2991_2998"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.2.207"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.2.213"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657709"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615393"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00003-3"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70093-4"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1185\/0300799009117021"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000273"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00010"},{"key":"e_1_2_1_71_1","unstructured":"Kiortsis DN Elisaf MS. Serum uric acid levels: A useful but not absolute marker of compliance with fenofibrate treatment. Fundamental and Clin Pharmacol (in press)"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.6.1301"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.12.1993"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.4.682"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002040050203"},{"key":"e_1_2_1_76_1","unstructured":"Tsimichodimos V Miltiadous G Bairaktari E et al. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol (in press)"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(98)00107-7"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00474-3"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00584-0"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05271-5"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00766-8"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00013-3"},{"key":"e_1_2_1_83_1","first-page":"171","article-title":"Preliminary report: ciprofibrate\u2013fluvastatin combination therapy for dyslipidemia","volume":"8","author":"Ganotakis ES","year":"1996","unstructured":"Ganotakis ES, Jagroop IA, Hamilton G, et al. Preliminary report: ciprofibrate\u2013fluvastatin combination therapy for dyslipidemia. J Drug Dev Clin Pract 1996;8:171\u20135","journal-title":"J Drug Dev Clin Pract"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03857.x"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(93)90056-T"},{"key":"e_1_2_1_86_1","first-page":"1518","article-title":"A novel treatment for refractory primary biliary cirrhosis?","volume":"47","author":"Miyaguchi S","year":"2000","unstructured":"Miyaguchi S, Ebinuma H, Imaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepato-Gastroenterology 2000;47:1518\u201321","journal-title":"Hepato-Gastroenterology"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754040-00007"},{"key":"e_1_2_1_88_1","first-page":"61B","article-title":"Fibrates: a review of important issues and recent findings","volume":"10","author":"Davignon P.","year":"1994","unstructured":"Davignon P. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994;10(Suppl B):61B\u201371B","journal-title":"Can J Cardiol"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.1.5"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00514-3"},{"key":"e_1_2_1_91_1","first-page":"156","article-title":"Clinical pharmacokinetics of fibric and derivatives (fibrates)","volume":"14","author":"Miller DB","year":"1998","unstructured":"Miller DB, Spence JD. Clinical pharmacokinetics of fibric and derivatives (fibrates). Clin Pharmacokinet 1998;14:156\u201362","journal-title":"Clin Pharmacokinet"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079902125000516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:04:46Z","timestamp":1770390286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079902125000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1185\/030079902125000516"],"URL":"https:\/\/doi.org\/10.1185\/030079902125000516","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}